Get the Stockscreener App
24.29
2.68%
0.635
Beam Therapeutics Inc stock is traded at $24.29, with a volume of 888.10K.
It is up +2.68% in the last 24 hours and up +4.59% over the past month.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
See More
Previous Close:
$23.65
Open:
$23.51
24h Volume:
888.10K
Relative Volume:
0.47
Market Cap:
$2.51B
Revenue:
$164.01M
Net Income/Loss:
$-65.04M
P/E Ratio:
-35.35
EPS:
-0.687
Net Cash Flow:
$-383.84M
1W Performance:
-1.28%
1M Performance:
+4.59%
6M Performance:
-20.84%
1Y Performance:
-10.68%
1-Day Range:
$23.20
$24.40
1-Week Range:
$23.28
$26.23
52-Week Range:
$20.23
$38.26
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
24.29 | 2.51B | 164.01M | -65.04M | -383.84M | -0.687 |
VRTX
Vertex Pharmaceuticals Inc
|
510.13 | 129.30B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.70 | 94.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.21 | 82.49B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.03 | 53.33B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
370.95 | 41.96B | 5.76B | 514.49M | 1.10B | 4.4813 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Initiated | Canaccord Genuity | Buy |
| Oct-09-25 | Initiated | Jefferies | Buy |
| Mar-28-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-10-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jan-29-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-23-24 | Initiated | H.C. Wainwright | Buy |
| Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
| Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-13-22 | Initiated | Citigroup | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Jan-05-22 | Initiated | Guggenheim | Buy |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Sep-24-21 | Resumed | Stifel | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Redburn | Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-16-21 | Initiated | Wells Fargo | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Aug-05-20 | Initiated | William Blair | Outperform |
| Mar-02-20 | Initiated | Barclays | Overweight |
| Mar-02-20 | Initiated | JP Morgan | Overweight |
| Mar-02-20 | Initiated | Jefferies | Buy |
| Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
Beam Therapeutics SVP Bethany Cavanagh Sells 187 Shares to Cover RSU Tax Withholding - Kalkine Media
To cover taxes, Beam Therapeutics (BEAM) treasurer sells 187 shares automatically. - Stock Titan
Beam Therapeutics Inc (NASDAQ: BEAM) Share Price, BEAM Stock News, BEAM Share Price & Updates - kalkine.ca
Beam Therapeutics (BEAM) president gifts shares to a family trust and retains 130,504 directly. - Stock Titan
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Motley Fool
Clinical Trial Progress Might Change The Case For Investing In Beam Therapeutics Stock (BEAM) - webull.com
Beam Therapeutics: Market Selling Phase 2 AATD Data Is Understandable, In My View - Seeking Alpha
Beam Therapeutics faces securities fraud probe after clinical trial safety concerns cause stock to drop 9.5%. - Pluang
Beam Therapeutics (BEAM) Restored AAT Levels. Can BEAM-302 Deliver Clinical Benefit? - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc.BEAM - PR Newswire
Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin DeficiencySlideshow (NASDAQ:BEAM) 2026-09-10 - Seeking Alpha
Beam Therapeutics Inc. (BEAM) Presents at European Respiratory Society (ERS) CongressSlideshow - Seeking Alpha
Beam Therapeutics at cantor conference: base editing lead comes into focus - Investing.com Canada
Cathie Wood’s ARK sells Alphabet stock, buys Meta and Beam Therapeutics - Investing.com
Beam Therapeutics at Citi summit: platform gains momentum across pipeline By Investing.com - Investing.com India
Beam Therapeutics at Citi summit: platform gains momentum across pipeline By Investing.com - Investing.com Canada
Beam Therapeutics at Citi summit: platform gains momentum across pipeline By Investing.com - Investing.com UK
Transcript : Beam Therapeutics Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 01 - marketscreener.com
Why (BEAM) Price Action Is Critical for Tactical Trading - Stock Traders Daily
A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $35 to $80 - Moomoo
BEAM Reiterated by Wedbush -- Price Target Maintained at $65 - GuruFocus
Beam Therapeutics (NasdaqGS:BEAM) Stock Forecast & Analyst Predictions - Simply Wall Street
BofA Securities Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $43 - Moomoo
BEAM Looks 14.6% Overvalued on GF Value™ - GuruFocus
Beam Therapeutics at Wells Fargo conference: base editing gains ground By Investing.com - Investing.com India
Beam Therapeutics at Wells Fargo conference: base editing gains ground By Investing.com - Investing.com UK
Beam drops after updating Phase 1/2 trial data for gene-editing drug - Seeking Alpha
3 Promising Genomics Stocks in the Spotlight in 2026 - TradingView
BEAM - Finviz
Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment - Yahoo Finance
Beam Therapeutics reports BEAM-302 AATD trial update - grafa.com
BEAM Looks 26.9% Overvalued on GF Value™ - GuruFocus
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 - manilatimes.net
Beam Therapeutics Presents Updated Clinical Data from the - GlobeNewswire
Beam Therapeutics (BEAM) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
BEAM Stock Price and Chart — NASDAQ:BEAM - TradingView
BEAM Should I Buy - Intellectia AI
Beam Therapeutics appoints Eric Foster as CCO - The Pharma Letter
Beam Therapeutics names Eric Foster as chief commercial officer By Investing.com - Investing.com Nigeria
Beam Therapeutics names Eric Foster as chief commercial officer By Investing.com - Investing.com South Africa
Beam Therapeutics names Eric Foster as chief commercial officer By Investing.com - Investing.com Canada
Beam Therapeutics names Eric Foster as chief commercial officer - Investing.com
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer - Barchart.com
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer - Stock Titan
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences - news.futunn.com
Three Beam Therapeutics talks will be webcast from Boston and New York - Stock Titan
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences - GlobeNewswire
Beam Therapeutics (BEAM) Stock May Look Stretched As Sales Expectations Climb - Yahoo Finance
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains - TradingView
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Beam Therapeutics Inc Stock (BEAM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Simon Amy | Chief Medical Officer |
Jul 27 '26 |
Sale |
25.74 |
16,667 |
429,037 |
85,696 |
| AMY SIMON | Officer |
Jul 27 '26 |
Proposed Sale |
25.74 |
16,677 |
429,294 |
0 |
| Simon Amy | Chief Medical Officer |
Jun 30 '26 |
Sale |
34.73 |
373 |
12,954 |
102,363 |
| Evans John M. | CEO |
Jun 30 '26 |
Option Exercise |
1.03 |
25,000 |
25,750 |
1,072,205 |
| Evans John M. | CEO |
Jun 30 '26 |
Sale |
34.31 |
25,000 |
857,685 |
1,047,205 |
| JOHN M EVANS | Officer |
Jun 30 '26 |
Proposed Sale |
34.31 |
25,000 |
857,685 |
0 |
| Evans John M. | CEO |
Jun 29 '26 |
Option Exercise |
0.76 |
25,000 |
19,031 |
1,072,205 |
| Evans John M. | CEO |
Jun 29 '26 |
Sale |
35.49 |
25,000 |
887,352 |
1,047,205 |
| JOHN M EVANS | Officer |
Jun 29 '26 |
Proposed Sale |
35.49 |
25,000 |
887,352 |
0 |
| FMR LLC | See Remark 1 |
Jun 26 '26 |
Sale |
35.26 |
251,488 |
8,867,467 |
854,583 |
4.60%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):